| Name | Title | Contact Details |
|---|
Concordant Inc is a North Chelmsford, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Coram Healthcare Corporation is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Denver, CO. To find more information about Coram Healthcare Corporation, please visit www.coramhc.com
PharmaBlock Sciences (Nanjing), Inc. is a leading innovative chemistry products and services provider throughout the pharmaceutical R&D process. Its core businesses include: a catalog of specially designed scaffolds and building blocks; custom synthesis; process development; manufacturing of key intermediates and RSMs; and FTE services. The company was listed on Shenzhen Exchange Stock in China on November 10, 2017. PharmaBlock has rapidly gained recognition for its outstanding capability in the design, synthesis, and supply of lab scale building blocks. Building on that success, the company acquired Shandong Diai Biotechnology Co., Ltd. as its pilot plant and manufacturing site in 2016, and is providing scale-up synthesis and manufacturing of key intermediates/RSMs. PharmaBlock is now committed to a more comprehensive and long-term service to valued customers.
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.
The HealthMyne Quantitative Imaging Decision Support (QIDS)® software platform and its Rapid Precise Metrics (RPM)™ functionality transform multiple clinical decision support workflows by combining quantitative imaging metrics with relevant patient information.